YIT’s Q3 results overall corresponded to expectations but was positive in terms of profitability of ...
DT’s Q3 wasn’t strong yet EBITA was better than estimated; Q4 should see further gradual gains, whil...
Raute’s Q3 figures were encouraging, and even if FY’26 EBITDA would decline more than we estimate th...
With the admission to the London Stock Exchange Main Market, at Friday, 31st October, and the prospe...
Redeye provides an initial comment on Tradedoubler’s Q3 2025 report.
* 38% y-o-y organic sales growth in Q3'25e * EBIT forecasts cut by 4.
* Adj. EBITA EUR 9.1m, above ABGSCe 7.0m and up y-o-y * We raise our adj.
* Organic momentum improved in all segments * A recovery in Swedish housing could drive 18% EBITA gr...
* Increasing activity in the letting market * Net financials miss in Q3 drives negative revisions * ...
* Q3 report Friday, 7 April at 08:30 CET * '25e-'27e adj.
Redeye updates on Gentoo Media ahead of Q3-results (due 18 November) where we expect limited topline...
Redeye reviews SynAct Pharma's Q3 report. The ADVANCE study is progressing and on track to enrol all...
Redeye provides a research update following the Q3 report published by OncoZenge earlier today.
Justerat för försäljningen av Gett och Tise var substansvärdet för VNV Global i linje med det andra ...
Redeye returns with a new note after gaining more insights from Monday’s webcast.
Lipum has presented new topline data from collaborative studies with Linköping University that stren...
Despite the profit warning released ahead of the Q3 report, there were also positives in the report ...
DT’s Q3 was challenging, but the bottom line result was a bit better than expected as the EUR 2.
YIT's net sales in Q3 amounted to EUR 402m (Evli/cons.
Oriola posted good figures in Q3. Net sales growth was nearly in the double-digits, while the adj.
